Myeloma Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Updates In Myeloma: Bispecific Antibodies & New Treatment Coming For Multiple Myeloma That Was Used In POEMS Syndrome
Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Care Discusses Updates In Myeloma: Bispecific Antibodies & New Treatment Coming For Multiple Myeloma That Was Used In POEMS Syndrom... Author: Annual-Meeting Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Updates In Myeloma: Bispecific Antibodies & amp; New Treatment Coming For Multiple Myeloma That Was Used In POEMS Syndrome
Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Center Discusses Updates In Myeloma: Bispecific Antibodies & New Treatment Coming For Multiple Myeloma That Was Used In POEMS S... Author: Annual-Meeting Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Connect MM Myeloma Disease Registry: This Is A Special Group Of Myeloma Patients Because They Respond To Venetoclax
Robert Rifkin MD Of US Oncology Research Discusses Connect MM Myeloma Disease Registry: This Is A Special Group Of Myeloma Patients Because They Respond To Venetoclax. Author: Annual-Meeting Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.
Katja Weisel from the University Medical Center Hamburg-Eppendorf discusses the efficacy and safety of daratumumab, bortezomib, and dexamethasone. Background: MM patients (pts) with high cytogeneti... Author: Annual-Meeting Added: 06/05/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2019 Category: Cancer & Oncology Source Type: podcasts

Myeloma Debate: Is MRD Ready for Prime Time? - No
Earn CME: <a target='_blank' href='https://naccme.com/program/7329'>https://naccme.com/program/...</a> In this presentation from the 'Minimal Residual Disease (MRD) Testing in Multiple Myeloma' symposium at the 2019 Great Debates & Updates in Hematologic... Author: imedex Added: 06/04/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2019 Category: Cancer & Oncology Source Type: podcasts

Myeloma Debate: Is MRD Ready for Prime Time? - Yes
Earn CME: <a target='_blank' href='https://naccme.com/program/7329'>https://naccme.com/program/...</a> In this presentation from the 'Minimal Residual Disease (MRD) Testing in Multiple Myeloma' symposium at the 2019 Great Debates & Updates in Hematologic... Author: imedex Added: 06/04/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2019 Category: Cancer & Oncology Source Type: podcasts

How Is Melflufen Different: Its A Lipophilic Peptide-Conjugated Alkylator That Rapidly Delivers A Highly Cytotoxic Payload Into Myeloma Cells Through Peptidase Activity
Jakob Lindberg CEO Of Oncopeptides Discusses How Is Melflufen Different: Its A Lipophilic Peptide-Conjugated Alkylator That Rapidly Delivers A Highly Cytotoxic Payload Into Myeloma Cells Through Pepti... Author: Annual-Meeting Added: 06/03/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2019 Category: Cancer & Oncology Source Type: podcasts

ACCC Educational Opportunities: Addressing Disease States Such As NSCLC, CLL, & Myeloma
Ali Mcbride @sheik2411 Of University of Arizona Cancer Center Discusses ACCC Educational Opportunities: Addressing Disease States Such As NSCLC, CLL, & Myeloma. Author: Annual-Meeting Added: 06/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 2, 2019 Category: Cancer & Oncology Source Type: podcasts

ACCC Educational Opportunities: Addressing Disease States Such As NSCLC, CLL, & amp; Myeloma
Ali Mcbride PharmD @sheik2411 Of University of Arizona Cancer Center Discusses ACCC Educational Opportunities: Addressing Disease States Such As NSCLC, CLL, & Myeloma. Author: Annual-Meeting Added: 06/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 2, 2019 Category: Cancer & Oncology Source Type: podcasts

Multiple Myeloma Update: Maintenance Therapy
Earn CME: <a target='_blank' href='https://naccme.com/program/7328'>https://naccme.com/program/...</a> In this presentation from the 'Updates on Treatment Approaches Across the Multiple Myeloma Spectrum' symposium at the 2019 Great Debates & Updates in H... Author: imedex Added: 05/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 2, 2019 Category: Cancer & Oncology Source Type: podcasts

Multiple Myeloma Update: Frontline Therapy
Earn CME: <a target='_blank' href='https://naccme.com/program/7328'>https://naccme.com/program/...</a> In this presentation from the 'Updates on Treatment Approaches Across the Multiple Myeloma Spectrum' symposium at the 2019 Great Debates & Updates in H... Author: imedex Added: 05/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 2, 2019 Category: Cancer & Oncology Source Type: podcasts

Emerging Immunotherapies in Multiple Myeloma
Earn CME: <a target='_blank' href='https://naccme.com/program/7328'>https://naccme.com/program/...</a> In this presentation from the 'Updates on Treatment Approaches Across the Multiple Myeloma Spectrum' symposium at the 2019 Great Debates & Updates in H... Author: imedex Added: 05/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 2, 2019 Category: Cancer & Oncology Source Type: podcasts

Novel Small Molecule Inhibitors in Multiple Myeloma
Earn CME: <a target='_blank' href='https://naccme.com/program/7328'>https://naccme.com/program/...</a> In this presentation from the 'Updates on Treatment Approaches Across the Multiple Myeloma Spectrum' symposium at the 2019 Great Debates & Updates in H... Author: imedex Added: 05/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 2, 2019 Category: Cancer & Oncology Source Type: podcasts

Sagar Lonial, MD, FACP - Innovative Therapeutic Concepts for ASCT-Eligible Patients With Myeloma: Advancing Toward More Effective Care Across Treatment Settings
Go online to PeerView.com/QAJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in myeloma offer guidance on the selection and sequencing of innovative therapies for the ASCT-eligible patients with multiple myeloma, and address several ongoing clinical questions from the choice of novel induction and maintenance options to minimal residual disease monitoring and th...
Source: PeerView CME/CE Audio Podcast - Immunology - April 22, 2019 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

Luciano J. Costa, MD, PhD - Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact of Novel Platforms and Agent Classes Across the Spectrum of Care
Go online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical findings and how to manage treatment-related adverse effects associated with emerging agent classes. Upon completion of this activity, partici...
Source: PeerView CME/CE Audio Podcast - Immunology - March 20, 2019 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts